Respiratory infection treating agent

Abstract

[Problem] The present invention pertains to a safer and more effective respiratory infection treating agent. [Solution] A respiratory infection treating agent containing, as an active ingredient, 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof.

1 . A respiratory infection treating agent comprising, as an active ingredient, 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The treating agent according to  claim 1 , wherein the respiratory infection treating agent is a respiratory infection treating agent for human. 
     
     
         3 . The treating agent according to  claim 1 , wherein the respiratory infection is one or two or more infections selected from the group consisting of pharyngitis, laryngitis, tonsillitis, acute bronchitis, pneumonia, and secondary infections of chronic respiratory diseases. 
     
     
         4 . The treating agent according to  claim 1 , wherein pathogenic bacteria causing the respiratory infection are one or two or more types of bacteria selected from the group consisting of bacteria belonging to  Staphylococcus  sp., bacteria belonging to  Streptococcus  sp.,  Moraxella catarrhalis , bacteria belonging to  Klebsiella  sp.,  Haemophilus influenzae , and  Escherichia coli.    
     
     
         5 . The treating agent according to  claim 1 , wherein pathogenic bacteria causing the respiratory infection are one or two or more types of bacteria belonging to any of  Streptococcus  sp. and  Staphylococcus  sp. 
     
     
         6 . The treating agent according to  claim 1 , wherein pathogenic bacteria causing the respiratory infection have drug resistance. 
     
     
         7 . The treating agent according to  claim 1 , wherein a dose of 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof per day is 10 mg or more and 250 mg or less. 
     
     
         8 . A treating agent for an infection which is one or two or more selected from the group consisting of pharyngitis, laryngitis, tonsillitis, acute bronchitis, pneumonia, secondary infections of chronic respiratory diseases, sinusitis, and tympanitis, and in which pathogenic bacteria are  Streptococcus pneumoniae , the treating agent comprising, as an active ingredient, 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof. 
     
     
         9 . The treating agent for an infection according to  claim 8 , wherein a dose of 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof per day is 10 mg or more and 250 mg or less. 
     
     
         10 . The treating agent according to  claim 1 , wherein a dose of 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof per day is 75 mg or two times the amount. 
     
     
         11 . A treating agent for an infection which is one or two or more selected from the group consisting of pharyngitis, laryngitis, tonsillitis, acute bronchitis, pneumonia, secondary infections of chronic respiratory diseases, sinusitis, and tympanitis, the treating agent comprising 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, wherein a dose of the compound per day is 75 mg or two times the amount. 
     
     
         12 . The treating agent according to  claim 1 , wherein a maximum plasma concentration of 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof after administration of the treating agent to human with a respiratory infection is 3 μg/mL or less. 
     
     
         13 . An infection treating agent containing 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof, wherein a tissue distribution ratio of the compound into an alveolar epithelial lining fluid 1 hour after administration to human is 10 or more.